More Images
TORONTO and NEW YORK—Binovi Technologies Corp. (TSX-V:VISN) has announced the appointment of Dr. Michael Gallaway to the Binovi scientific advisory board. Dr. Gallaway joins the other members of the board in directing the company’s advancements, according to a recent announcement. “We are very pleased to welcome Dr. Gallaway to the scientific advisory board. His extensive experience working with children will help tremendously as we push Binovi into the education sector, with our focus on K-12—and particularly K-3—students,” Binovi chief executive officer Adam Cegielski said in the announcement.

“I am delighted that Dr. Gallaway has joined our Scientific Advisory Board. His background in scientific research, vision-based learning problems, vision screening, and concussion management, will help take Binovi to another level,” added Dr. Leonard Press, Binovi’s chief scientific officer.

Dr. Gallaway is board certified in vision therapy as a Fellow in the College of Optometrists in Vision Development (COVD), and is a Fellow in the American Academy of Optometry (AAO). He has been in private practice in the South Jersey area since 1989, specializing in vision therapy and children’s vision disorders. He is also an associate professor at the Pennsylvania College of Optometry at Salus University in Philadelphia.

In addition to his teaching, he is involved in research in learning related vision problems, amblyopia, vision therapy for convergence insufficiency, and concussion-related vision problems.

Binovi is a best-in-class neuro-visual performance platform designed to test, analyze, track, and report on individual cognitive performance. Binovi combines hardware, software, specialized expert knowledge, and unique data insights to deliver customized, one-on-one training and learning protocols ideal for K-12 Students, Vision Care Specialists, and Sports Performance testing and training.